MariMed (MRMD) Projected to Post Quarterly Earnings on Wednesday

MariMed (OTCMKTS:MRMD) is expected to be releasing its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect MariMed to post earnings of ($0.01) per share and revenue of $40.80 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 8:00 AM ET.

MariMed Trading Up 6.0%

Shares of MariMed stock opened at $0.08 on Monday. The stock has a market capitalization of $33.55 million, a P/E ratio of -2.12 and a beta of 1.11. MariMed has a 52-week low of $0.07 and a 52-week high of $0.23. The company has a debt-to-equity ratio of 1.34, a quick ratio of 0.35 and a current ratio of 1.06. The stock’s 50-day simple moving average is $0.09 and its 200 day simple moving average is $0.11.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on MRMD shares. Ventum Financial lowered shares of MariMed from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 7th. Zacks Research upgraded shares of MariMed from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

MariMed Company Profile

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.